LINC AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.7 SEK | -0.46% |
|
+5.22% | -0.15% |
| Apr. 22 | Linc AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Jan. 25 | Linc AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Sales 2022 | -892M -82.09M | Sales 2023 | 659M 60.68M | Capitalization | 3.74B 344M |
|---|---|---|---|---|---|
| Net income 2022 | -723M -66.52M | Net income 2023 | 619M 56.95M | EV / Sales 2022 | -3.19 x |
| Net cash position 2022 | 601M 55.26M | Net cash position 2023 | 520M 47.84M | EV / Sales 2023 | 4.88 x |
| P/E ratio 2022 |
-4.76
x | P/E ratio 2023 |
6.04
x | Employees | 2 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 37.63% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.77% | ||
| 1 week | +5.22% | ||
| Current month | +3.04% | ||
| 1 month | +5.22% | ||
| 3 months | +6.44% | ||
| 6 months | +20.56% | ||
| Current year | -0.15% |
1 week
61.50
65.60
1 month
59.7065.60
Current year
59.4067.80
1 year
52.2079.00
3 years
43.80118.20
5 years
43.80118.20
10 years
43.80118.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 19-12-31 | |
Thomas Bergh
DFI | Director of Finance/CFO | 42 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 71 | 90-12-31 | |
Ulrika Dellby
BRD | Director/Board Member | 58 | 19-12-31 |
| Director/Board Member | 65 | 19-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 64.7 | -0.46% | 1 011 |
| 24-04-22 | 65 | +1.72% | 38,207 |
| 24-04-19 | 63.9 | 0.00% | 46,366 |
| 24-04-18 | 63.9 | +0.63% | 46,577 |
| 24-04-17 | 63.5 | +3.59% | 81,484 |
Delayed Quote Nasdaq Stockholm, April 23, 2024 at 04:32 am EDT
More quotes
Linc Invest AB is a Sweden-based investment company. Linc invests in product-oriented companies within the Nordic Life Science industry - primarily in pharmaceutical and medical technology companies. The investments are made in both private and public companies and in research and operational companies. Typically, investments in drug development take place in an earlier phase compared to investments in medical technology. Linc Invest is an active and long-term owner with a wide industrial network to support the portfolio companies. The Company works together with the management, founders and board to realize the inherent potential that exists in the investment, have ambitious plans for further development and expansion and actively participate in the nomination committee work.
Calendar
2024-07-17
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -0.15% | 345M | |
| +3.91% | 139M |
- Stock Market
- Equities
- LINC Stock
